Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

By BiotechDaily International staff writers
Posted on 31 Jul 2014
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).
A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose metabolism.

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) worked with a mouse model of diet-induced diabetes, the rodent equivalent of human type II diabetes. Previous studies had shown that when these mice were prevented from producing FGF1 and then placed on a high-fat diet, they quickly developed diabetes.

In the current study, the investigators expanded research on the link between FGF1 and diabetes by greatly increasing FGF1 levels in the mice. This was done by injecting the animals with one or more doses of recombinant FGF1 (rFGF1).

Results published in the July 16, 2014, online edition of the journal Nature revealed that the single dose of rFGF1 caused potent, insulin-dependent lowering of glucose levels in diabetic mice that was dose-dependent but did not lead to hypoglycemia. Chronic pharmacological treatment with rFGF1 increased insulin-dependent glucose uptake in skeletal muscle and suppressed production of glucose in the liver to achieve whole-body insulin sensitization. The sustained glucose lowering and insulin sensitization attributed to rFGF1 were not accompanied by the side effects of weight gain, fat accumulation in the liver, and bone loss associated with current insulin-sensitizing therapies. In addition, the glucose-lowering activity of FGF1 could be dissociated from its mitogenic activity and was mediated predominantly via FGF receptor 1 signaling.

"There are many questions that emerge from this work and the avenues for investigating FGF1 in diabetes and metabolism are now wide open," said senior author Dr. Ronald M. Evans, director of the gene expression laboratory at the Salk Institute for Biological Studies. "We want to move this to people by developing a new generation of FGF1 variants that solely affect glucose and not cell growth. If we can find the perfect variation, I think we will have on our hands a very new, very effective tool for glucose control."

Related Links:

Salk Institute for Biological Studies



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.